A Phase IIb Study of OligoG in Subjects With Cystic Fibrosis

Summary

The purpose of the study is assessment of efficacy and safety of OligoG as a dry powder formulation, in adult subjects with cystic fibrosis.

Timeline

Start

2014-10

Primary completion

2017-01

Completion

2017-09

Publications

• Hurley MN, Smith S, Forrester DL, Smyth AR. Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis. Cochrane Database Syst Rev. 2020 Jul 16;7(7):CD008037. doi: 10.1002/14651858.CD008037.pub4.

Drugs

Indications